ClinicalTrials.gg
RecruitingNCT07113184DOBLE UPUpdated Nov 10, 2026

Randomized a Clinical Trial With Medical Device in Acute Ischemic Stroke

An interventional study of dual sr and single sr in Acute Ischemic Stroke, sponsored by Instituto de Investigación Marqués de Valdecilla. Recruiting at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Instituto de Investigación Marqués de Valdecilla · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 137 studies in Ischemic Stroke with a site in Spain — 37 open to participants now, 46 under way, 7 of them phase 3. Ischemic Stroke · Spain.

Planned enrollment
54th of 97
220 · median 240
Started
2026
with 9 others
No phase
48 of 137
15 open now
Primary completion
2027-03
later than 23 of 45 live
Registered
123rd of 137
by date

Among the 137 studies in Ischemic Stroke with a site in Spain, this one is the 54th largest by planned enrollment of the 97 interventional ones that give a count, is one of 10 that started in 2026, is one of 48 with no phase, reaches primary completion later than 23 of the 45 other live ones, and was the 123rd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

37 of the 137 studies in Ischemic Stroke with a site in Spain are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Ischemic Stroke with a site in Spain, or all of them as a file.
02

Study summary

This study seeks to provide high-quality evidence on the potential benefits of the dual stentriever approach, potentially informing future clinical guidelines and improving outcomes in patients with anterior circulation large vessel occlusion strokes.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute ischemic stroke
  • mechanical thrombectomy
  • dual stentriever
  • mTICI
  • first pass effect
  • randomized trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18
  • NIHSS ≥ 6
  • mRS ≤ 1
  • Proximal anterior circulation occlusion
  • ASPECTS > 6

Exclusion criteria

Exclusion Criteria:

  • Absence of occlusion
  • Posterior circulation stroke
  • Carotid dissection or tandem stenosis requiring treatment
  • Severe comorbidities or to imaging contrast
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Dual Stentriever

    Endovascular mechanical thrombectomy with dual or stentriever technique using a balloon guiding catheter.

    Device: dual sr

  • Active comparator
    Single Stentriever

    Endovascular mechanical thrombectomy with single stentriever technique using a balloon guiding catheter.

    Device: single sr

Interventions

  • Devicedual sr

    Dual Stentriever

    Also known as: experimental

  • Devicesingle sr

    Single Stentriever

    Also known as: control

06

What researchers measure

Primary outcomes

  1. Time takes in achieving complete reperfusion after a single thrombectomy pass.

    To evaluate the superiority of the dual stentriever technique in achieving complete reperfusion after a single thrombectomy pass.

    Time frame: 24 hours or 48 hours after thrombectomy

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 12 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Oct 2025 → Mar 2026, primary completion Nov 2026 → Mar 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Aug 8, 2025
StartActual
Mar 1, 2026was Oct 2025
Primary completionEst.
Mar 1, 2027was Nov 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Hospital de Burgos · Burgos, Spainno status→Recruiting
  • Complejo Hospitalario de Salamanca · Salamanca, Spainno status→Recruiting
  • Hospital universitario marques de valdecilla · Santander, Spainno status→Recruiting
Show site
  • Hospital Regional de Málaga · Málaga, Spain
Nov 10, 2026
Start date
Oct 1, 2025→Mar 1, 2026 (actual)
Nov 10, 2026
Primary completion
Nov 1, 2026→Mar 1, 2027
Nov 10, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 10, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Hospital de Burgos · Burgos, SpainContact added j•••@saludcastillayleon.es
  • Complejo Hospitalario de Salamanca · Salamanca, SpainContact added e•••@saludcastillayleon.es
  • Hospital universitario marques de valdecilla · Santander, SpainContact added a•••@scsalud.es
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    1 site added. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Hospital de Burgos · Burgos, Spainno status→Recruiting
    • Complejo Hospitalario de Salamanca · Salamanca, Spainno status→Recruiting
    • Hospital universitario marques de valdecilla · Santander, Spainno status→Recruiting
    Show site
    • Hospital Regional de Málaga · Málaga, Spain
    Start date Oct 1, 2025→Mar 1, 2026 (now actual)
    Primary completion Nov 1, 2026→Mar 1, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Hospital de Burgos · Burgos, SpainContact added j•••@saludcastillayleon.es
    • Complejo Hospitalario de Salamanca · Salamanca, SpainContact added e•••@saludcastillayleon.es
    • Hospital universitario marques de valdecilla · Santander, SpainContact added a•••@scsalud.es
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07113184
Lead sponsor
Instituto de Investigación Marqués de Valdecilla
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Mar 1, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion